Literature DB >> 24108665

Oliguria during hydrocortisone dosage wean in very low birth weight infants.

J B Sauberan1, E M Reed1, Y V Vaucher1, A C Katheria1.   

Abstract

BACKGROUND: Intravenous hydrocortisone (HC) is often used in very low birth weight infants (VLBW) but can be complicated by oliguria when discontinued or tapered.
OBJECTIVES: To determine which factors were associated with oliguria during HC taper.
METHODS: We reviewed all VLBW infants who received initial doses of HC ≥ 1 mg/kg/d. The initial dose and duration of HC, and the incidence of oliguria (urine output [UO] < 2 mL/kg/h) during HC taper, were recorded. In those with oliguria, we recorded the change in UO (mL/kg/h), blood pressure, and creatinine.
RESULTS: The mean initial HC dose was 2.8 ± 1 mg/kg/d, and the mean total duration of HC therapy was 23 ± 25 days. Oliguria occurred in 24% (13/54) of treated infants. These infants were exposed to higher and longer duration of the initial HC dose than infants without oliguria. Oliguria was predicted by the initial HC dose (odds ratio [OR] 5.8, 95% confidence interval [CI] 1.3-25.8, p = 0.02) and by the number of days at initial dose (OR 1.7, 95%CI 1.1-2.7, p = 0.03).
CONCLUSIONS: Oliguria during HC dosage weaning was associated with higher initial HC exposure. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24108665     DOI: 10.1055/s-0033-1357264

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  1 in total

1.  Presumed adrenal insufficiency in neonates treated with corticosteroids for the prevention of bronchopulmonary dysplasia.

Authors:  Justin B Josephsen; Brianna M Hemmann; Connie D Anderson; Brett M Hemmann; Paula M Buchanan; Howard L Williams; Lisa M Lubsch; Noah H Hillman
Journal:  J Perinatol       Date:  2021-11-01       Impact factor: 2.521

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.